| FENOLDOPAM MESYLATE
Classifications: non-nitrate vasodilator; dopamine agonist agent; antihypertensive; Therapeutic: non-nitrate vasodilator; antihypertensive
Pregnancy Category: B
10 mg/mL injection
Rapid-acting vasodilator that is a dopamine D1-like receptor agonist. Exerts hypotensive effects by decreasing peripheral vascular resistance while increasing renal blood
flow, diuresis, and natriuresis.
Indicated by rapid reduction in BP. Decreases both systolic and diastolic pressures.
Short-term (up to 48 h) management of severe hypertension.
Hypersensitivity to fenoldopam. Avoid concomitant use with beta blockers.
Asthmatic patients; hepatic cirrhosis, portal hypertension, or variceal bleeding; arrhythmias, tachycardia, or angina, particularly
unstable angina; elevated IOP; angular-closure glaucoma; hypotension; hypokalemia; acute cerebral infarct or hemorrhage; pregnancy
(category B), lactation.
Route & Dosage
Adult: IV 0.10.3 mcg/kg/min by continuous infusion for up to 48 h, may increase by 0.050.1 mcg/kg/min q15min (dosage range:
Child: IV 0.2 mcg/kg/min, may increase to 0.30.5 mcg/kg/min
PREPARE: Continuous for Adult: Dilute to a final concentration of 40 mcg/mL by adding 1 mL (10 mg), 2 mL (20 mg), or 3 mL (30 mg) of fenoldopam to 250, 500,
or 1000 mL, respectively, of NS or D5W. Continuous for Child: Dilute to a final concentration of 60 mcg/mL by adding 0.6 mL (6 mg), 1.5 mL (15 mg) or 3 mL (3 mg) of fenoldopam to 100,
250, or 500 mL, respectively, of NS or D5W.
ADMINISTER: Continuous for Adult/Child: Give only by continuous infusion; never give a direct or bolus dose. Titrate initial dose up or down no more frequently than
INCOMPATIBILITIES Y-site: Aminophylline, ampicillin, amphotericin B, bumetanide, cefoxitin, dexamethasone, diazepam, fosphenytoin, furosemide, ketorolac, methohexital, methylprednisolone, pentobarbital, phenytoin, prochlorperazine, sodium bicarbonate, thiopental.
- Note: Diluted solution is stable under normal room temperature and light for 24 h. Discard any unused solution after 24 h.
- Store at 15°30° C (59°86° F) in a tightly closed container and protect from light.
Adverse Effects (≥1%) Body as a Whole:
Injection site reaction, pyrexia, nonspecific chest pain. CNS:
Headache, nervousness, anxiety, insomnia
, dizziness. CV: Hypotension, tachycardia,
T-wave inversion, flushing, postural hypotension, extrasystoles, palpitations, bradycardia, heart failure, ischemic heart
, angina. GI:
Nausea, vomiting, abdominal pain or fullness, constipation
, BUN, glucose, transaminases, LDH; hypokalemia. Respiratory:
Nasal congestion, dyspnea
, upper respiratory disorder. Skin:
UTI, leukocytosis, bleeding.
Use with beta-blockers
increases risk of hypotension.
5 min. Peak:
15 min. Duration:
1530 min. Distribution:
Crosses placenta. Metabolism:
Conjugated in liver. Elimination:
90% in urine, 10% in feces. Half-Life:
Assessment & Drug Effects
- Monitor BP and HR carefully at least q15min or more often as warranted; expect dose-related tachycardia.
- Lab tests: Carefully monitor serum electrolytes (especially serum potassium), BUN and creatinine, liver enzymes, and blood
glucose and HbA1C.